Abbott Vascular's Absorb Bioresorbable Vascular Scaffold Studied for BTK Treatment
August 30, 2016—In 12-month clinical and imaging follow-up, the Absorb everolimus-eluting bioresorbable vascular scaffold (Abbott Vascular) demonstrated excellent safety, patency, and freedom from target lesion revascularization for the treatment of below-the-knee (BTK) arteries, concluded Ramon L. Varcoe, MBBS, et al in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions (2016;9:1721–1728).
